Suppr超能文献

大隐静脉腔内激光消融术后低位残端反流的发生率降低。

Lower prevalence of stump reflux after endovenous laser flush ablation of the great saphenous vein.

机构信息

Dr. Maurins Vein Clinic, Riga, Latvia.

Private Practice Dermatology & Phlebology, Bonn, Germany.

出版信息

Vasa. 2022 Jul;51(4):222-228. doi: 10.1024/0301-1526/a001007. Epub 2022 May 9.

Abstract

This single center prospective randomized study was performed to compare the effect of endovenous laser flush ablation (EVLAf) of the great saphenous vein (GSV) close to the sapheno-femoral junction (SFJ) with a standard ablation (EVLAs) up to two cm distally of the SFJ on reflux in the GSV stump. Between April 2013 and January 2016, 146 legs in 146 consecutive patients, meeting the inclusion/exclusion criteria, were treated by EVLA. All patients were randomized into 2 groups. In group 1 EVLAf started from the SFJ level, and in group 2 EVLAs started two cm below the SFJ. The primary endpoint was reflux in the GSV stump after 900 days. Secondary endpoints were reflux in the anterior accessory saphenous vein (AASV), proximal clinically recurrent varicose veins related to reflux in the stump and/or the AASV. At day 900, 27 patients were lost to follow-up. Reflux in the stump was detected in 3.6% in group 1 and in 22.2% in group 2 (p<0.05). Reflux in the AASV was present in 7.1% in group 1 and in 17.46% in group 2 (p=0.09). Proximal clinically recurrent varicose veins were observed in 8.9% in group 1 and in 19.1% in group 2 (p=0.12). The greatest diameter of the stump was significantly larger in group 2 (group 1: 0.41 cm, group 2: 0.6 cm, p<0.001). EVLAf is associated with a significantly lower incidence of reflux in the GSV stump, with a trend to a lower incidence of reflux in the AASV and with a lower incidence of proximal recurrent varicose veins after 900 days follow-up compared to EVLAs. EVLAf may improve the clinical recurrence rate after EVLA of the GSV.

摘要

这项单中心前瞻性随机研究旨在比较静脉内激光冲洗消融(EVLAf)在大隐静脉(GSV)接近隐股交界处(SFJ)处与标准消融(EVLAs)至 SFJ 下方两厘米处对 GSV 残端反流的影响。2013 年 4 月至 2016 年 1 月,符合纳入/排除标准的 146 例连续患者的 146 条肢体接受了 EVLA 治疗。所有患者均随机分为 2 组。在第 1 组中,EVLAf 从 SFJ 水平开始,而在第 2 组中,EVLAs 从 SFJ 下方两厘米处开始。主要终点是 900 天后 GSV 残端的反流。次要终点是前辅助隐静脉(AASV)的反流、与残端和/或 AASV 反流相关的近端临床复发性静脉曲张。在第 900 天,有 27 名患者失访。第 1 组中有 3.6%的患者残端有反流,而第 2 组中有 22.2%的患者残端有反流(p<0.05)。第 1 组中有 7.1%的患者 AASV 有反流,而第 2 组中有 17.46%的患者 AASV 有反流(p=0.09)。第 1 组中有 8.9%的患者近端临床复发性静脉曲张,而第 2 组中有 19.1%的患者近端临床复发性静脉曲张(p=0.12)。第 2 组的残端最大直径明显大于第 1 组(第 1 组:0.41cm,第 2 组:0.6cm,p<0.001)。与 EVLAs 相比,EVLAf 与 GSV 残端反流发生率显著降低相关,与 AASV 反流发生率降低趋势相关,与 900 天随访后近端复发性静脉曲张发生率降低相关。EVLAf 可能会提高 GSV 的 EVLA 后的临床复发率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验